6
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Methylprednisolone Accelerates the Resolution of Glomerulonephritis by Sensitizing Mesangial Cells to Apoptosis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glucocorticoid has long been used to treat patients with glomerulonephritis because it ameliorates mesangial cell proliferation and proteinuria, in part by suppressing nuclear factor-kappa B (NF-ĸB) activation, which regulates the transcription of various pro-inflammatory genes. Recent evidence shows that NF-ĸB activation increases the resistance to TNF-α-induced apoptosis in mesangial cells. We examined glomerular cell proliferation and apoptosis along with NF-ĸB activation in the Thy-1.1 nephritis model. We also evaluated TNF-α-induced apoptosis in cultured mesangial cells. Methylprednisolone treatment ameliorated mesangial hypercellularity in Thy-1.1 nephritis by decreasing proliferating cells and increasing apoptosis in the glomeruli. These effects were associated with suppressed NF-ĸB activation. This in vitro study revealed that treatment with methylprednisolone and TNF-α induced cultured mesangial cell apoptosis. These results suggest that methylprednisolone may accelerate the resolution phase of Thy-1.1 nephritis in part by sensitizing mesangial cells to apoptosis.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.

          Studies on mice deficient in nuclear factor kappa B (NF-kappaB) subunits have shown that this transcription factor is important for lymphocyte responses to antigens and cytokine-inducible gene expression. In particular, the RelA (p65) subunit is required for induction of tumor necrosis factor-alpha (TNF-alpha)-dependent genes. Treatment of RelA-deficient (RelA-/-) mouse fibroblasts and macrophages with TNF-alpha resulted in a significant reduction in viability, whereas RelA+/+ cells were unaffected. Cytotoxicity to both cell types was mediated by TNF receptor 1. Reintroduction of RelA into RelA-/- fibroblasts resulted in enhanced survival, demonstrating that the presence of RelA is required for protection from TNF-alpha. These results have implications for the treatment of inflammatory and proliferative diseases.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Suppression of TNF-alpha -Induced Apoptosis by NF-kappa B

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-kappa B

                Bookmark

                Author and article information

                Journal
                EXN
                Nephron Exp Nephrol
                10.1159/issn.1660-2129
                Cardiorenal Medicine
                S. Karger AG
                1660-2129
                2001
                2001
                31 August 2001
                : 9
                : 5
                : 317-326
                Affiliations
                Departments of aMedicine III and bAnatomy I, Okayama University Medical School, Okayama, Japan
                Article
                52627 Exp Nephrol 2001;9:317–326
                10.1159/000052627
                11549849
                3ea9f0e6-88f3-4234-ab0f-9b34be1fe67f
                © 2001 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Page count
                Figures: 6, Tables: 1, References: 49, Pages: 10
                Categories
                Original Paper

                Cardiovascular Medicine,Nephrology
                Apoptosis,NF-ĸB,Methylprednisolone,Glomerulonephritis,Mesangial cell

                Comments

                Comment on this article